Effects of Androgen Receptor and Androgen on Gene Expression in Prostate Stromal Fibroblasts and Paracrine Signaling to Prostate Cancer Cells by Tanner, Matthew J. et al.
Effects of Androgen Receptor and Androgen on Gene
Expression in Prostate Stromal Fibroblasts and Paracrine
Signaling to Prostate Cancer Cells
Matthew J. Tanner






4, Badar M. Mian
2,3, Ralph Buttyan
1,2*
1Ordway Research Institute, Albany, New York, United States of America, 2Division of Urology, Department of Surgery, Albany Medical College, Albany, New York, United
States of America, 3Stratton Veterans Affairs Medical Center, Albany, New York, United States of America, 4Department of Urology, Roswell Park Cancer Institute, Buffalo,
New York, United States of America
Abstract
The androgen receptor (AR) is expressed in a subset of prostate stromal cells and functional stromal cell AR is required for
normal prostate developmental and influences the growth of prostate tumors. Although we are broadly aware of the
specifics of the genomic actions of AR in prostate cancer cells, relatively little is known regarding the gene targets of
functional AR in prostate stromal cells. Here, we describe a novel human prostate stromal cell model that enabled us to
study the effects of AR on gene expression in these cells. The model involves a genetically manipulated variant of
immortalized human WPMY-1 prostate stromal cells that overexpresses wildtype AR (WPMY-AR) at a level comparable to
LNCaP cells and is responsive to dihydrotestosterone (DHT) stimulation. Use of WPMY-AR cells for gene expression profiling
showed that the presence of AR, even in the absence of DHT, significantly altered the gene expression pattern of the cells
compared to control (WPMY-Vec) cells. Treatment of WPMY-AR cells, but not WPMY-Vec control cells, with DHT resulted in
further changes that affected the expression of 141 genes by 2-fold or greater compared to vehicle treated WPMY-AR cells.
Remarkably, DHT significantly downregulated more genes than were upregulated but many of these changes reversed the
initial effects of AR overexpression alone on individual genes. The genes most highly effected by DHT treatment were
categorized based upon their role in cancer pathways or in cell signaling pathways (transforming growth factor-b, Wnt,
Hedgehog and MAP Kinase) thought to be involved in stromal-epithelial crosstalk during prostate or prostate cancer
development. DHT treatment of WPMY-AR cells was also sufficient to alter their paracrine potential for prostate cancer cells
as conditioned medium from DHT-treated WPMY-AR significantly increased growth of LNCaP cells compared to DHT-treated
WPMY-Vec cell conditioned medium.
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Introduction
The prostate gland requires androgenic steroids for development,
adult maintenance and function. Males with inactivating mutations
in key genes required for androgen metabolism develop only a
rudimentary prostate gland [1] and males with inactivating
mutations in the androgen receptor (AR) gene, that mediates the
effects of androgens, do not develop prostates [2]. Androgens and
AR action also play an important role in prostate carcinogenesis.
Drugs that inhibit androgen biosynthesis have chemopreventative
effects that significantly reduce the risk for developing prostate
cancerinmen [3]andandrogenablation therapiesprovide themost
clinically useful means for palliative disease control when prostate
cancer is detected in the advanced stage [4]. These clinical facts
identify the relevance of androgen signaling for prostate biology and
carcinogenesis and drive research efforts to characterize the
consequences of androgen signaling in prostate cells.
Since the AR protein is an extended member of the nuclear
transcription factor that conditionally regulates the expression of
genes [5], it is reasonable to expect that the availability of a
comprehensive catalogue of androgen regulated genes in prostate
cells could significantly contribute to our knowledge of androgen
action in the prostate. To this end, the use of contemporary mass
gene expression profiling technology, especially involving gene
microarrays on Chips, has already greatly expanded the list of
known androgen regulated genes in prostate cancer cells [6–9].
Studies using this approach have supported the eventual
identification of novel genetic anomalies (ETS gene rearrange-
ments) [10–12] and have helped to identify abnormally active
signaling pathways in prostate cancer cells [13,14] that have
translational potential for improving prostate cancer diagnostic or
treatment strategies. This type of technology, however, has not yet
been used to characterize androgen/AR effects on gene expression
in prostate stromal cells, despite the extensive evidence that cells
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16027from the prostate stroma actively participate in the processes
through which androgens regulate normal or malignant prostate
development [15–19]. The principal reason for this deficit is the
lack of suitable cultured human prostate stromal cell models that
robustly express the AR protein and are demonstrably responsive
to the presence of androgens as indicated by changes in gene
expression when cultured in an androgen containing medium.
Here, we describe our experience in testing some available
(benign) human prostate stromal cell models for their responsive-
ness to androgens in vitro and in developing a specific androgen-
responsive human prostate stromal cell model (WPMY-AR cells)
that was profiled for AR- and androgen-induced changes in gene
expression using human gene Chip microarrays. Furthermore, we
used this model cell system to test the idea that androgens alter the
paracrine signaling environment of a prostate tumor by affecting
the output of secreted factors from prostate stromal fibroblasts.
Results
Androgen receptor expression and activity in cultured
human prostate stromal cells
Two available immortalized human prostate stromal cell lines,
PS-30 and WPMY-1, and non-immortalized primary human
prostate stromal cell myofibroblasts were evaluated for AR
expression and responsiveness to androgens. None of these cells
require androgen for in vitro growth, however, WPMY-1 cells were
previously reported to grow slightly faster in the presence of
synthetic androgen, R1881 [20]. AR expression was assessed in
these cells by quantitative RT-PCR (qPCR) and Western blot
procedures and was compared to cultured primary human prostate
stromal fibroblasts (PrSC) and to LNCaP prostate cancer cells that
are models for AR action in prostate cancer (Figure 1A). Of the
surveyed cells, LNCaP cells expressed the highest levels of AR
mRNA. AR mRNAwasexpressedat only 3.4% ofthislevelinPS30
cells, 1.1% inPrSC and at slightly over 0.1%of this level inWPMY-
1 cells. This pattern was consistent with our Western blot data
where we were unable to detect a band corresponding to AR in
extracts of either of the immortalized cells or in PrSC though it was
readily detected in the extract from LNCaP cells (Fig. 1B). Likewise,
when parental WPMY-1 cells were transfected with an androgen
responsive reporter vector, they showed no evidence of increased
expression of the reporter (luciferase) in response to increasing
amounts of DHT(Fig. 1C). However, when WPMY-1cellswereco-
transfectedwith the androgenreporter along withan AR expression
vector, the expression of the reporter was significantly increased by
the presence of DHT (Fig. 1C). In summary, the low endogenous
AR expression in these human prostate stromal cell lines and their
unresponsiveness to androgen stimulation suggests that they are
poor models for the study of androgen action in stromal cells, but
exogenous expression of AR, at least in the WPMY-1 cells,
conferred upon these cells an androgen-responsive phenotype that
could be more conducive to the study of androgen action.
In order to make WPMY-1 cells more amenable for the study of
androgen effects on gene expression, we transduced the cells with
human wildtype AR expression lentivirus and then used antibiotic
selection to obtain a stable population of AR overexpressing
WPMY-1 cells (WPMY-AR). Other WPMY-1 cells were trans-
duced with empty lentivirus and selected under the same
conditions to obtain a control cell population (WPMY-Vec).
WPMY-AR cells express AR mRNA and protein at a level
comparable with androgen-sensitive LNCaP prostate cancer cells
(Figs. 1A, B). Immunofluorescence staining using anti-AR
antibody showed that AR was mostly in the cytoplasm when
these cells were grown in the absence of DHT, although there was
light nuclear immunofluorescent staining in most cells (Fig. 1D). In
contrast, when WPMY-AR cells were grown in DHT-containing
medium, AR immunostaining was exclusively nuclear. The AR
expressed in the stable WPMY-AR cells was functional for
genomic activation of gene expression. When these cells were
transfected with the androgen-reporter, luciferase activity was
significantly increased by treatment with DHT whereas DHT did
not affect luciferase expression in reporter-transfected WPMY-Vec
control cells (Fig. 1E). Otherwise, WPMY-AR cells showed no
other overt phenotypic differences when compared to WPMY-Vec
control cells; they were indistinguishable by morphology under
microscopic observation (not shown) and have similar growth rates
in both androgen-free and androgen-containing medium (Fig. 1F).
Comparative Gene Expression Profiling of Prostate
Stromal Cell Variants Grown in the Presence or Absence
of DHT
WPMY-Vec and WPMY1-AR cells were plated in equal
numbers in androgen-free medium for attachment then trans-
ferred to fresh medium with or without supplemental 10 nM DHT
for 72 hrs. RNAs extracted from biological duplicates of these
cultures were labeled then profiled on Affymetrix Human Gene
ST 1.0 Array Gene Chips. The microarray expression data was
analyzed to identify those genes that were differentially expressed
between a given cell under differing conditions (2/+ DHT) or
between the two cell types (WPMY-Vec vs WPMY-AR) under
equivalent conditions. Using a cutoff of 1.5-fold changes in RNA
expression, WPMY-Vec control cells had only 8 genes that were
differentially expressed in the presence of DHT and the graph
showing the range of these changed genes was generated by the
GeneSpring program and is shown in Figure 2A. We attempted to
confirm differential expression of these 8 genes in WPMY-Vec
DHT-treated/-untreated cells using real-time qPCR to assess
expression of each gene on a fresh set of biological duplicate
samples but the outcomes of this analysis showed no significant
differences in expression for any of them using this method (not
shown). Comparison of the gene expression profiles of DHT-
treated/-untreated WPMY-AR cells, however, did show much
more striking and robust changes in gene expression associated
with DHT treatment. DHT affected the expression of 172
individual genes by 1.5-fold or greater (Fig. 2B). However, the
majority of these changes (141 or 81.9%) were at the level of 2-fold
or greater. In this latter category, more genes were downregulated
by DHT (85 genes) than were upregulated (56 genes). The genes
that were changed by 2-fold or greater are identified in Table S2
and Table S3. We then chose 10 different genes from these lists,
including 6 upregulated and 4 downregulated genes, for further
validation by real-time qPCR on a fresh set of RNAs extracted
from biological duplicate samples. Each of these selected genes was
confirmed to be significantly up- or down-regulated by the
presence of DHT in the same manner as the results of the
microarray expression analysis (Fig. 3A). Finally, the list of genes
(up- and down-regulated) that were changed by 2-fold or greater in
the presence of DHT was functionally assessed using the Pathway
Express software program (http://vortex.cs.wayne.edu/projects.
htm) [21] that assigns genes into specific KEGG functional
pathways and then the different KEGG pathways associated with
these genes were quantitatively prioritized by either of two
different parameters: 1) the number of input genes that are
assigned to a specific KEGG pathway; or 2) the percent of
individual KEGG pathway genes that were present in the input
gene set (Table 1). The top 10 KEGG pathway rankings using the
two different parameters shared the categories, Pathways in
Cancer, Cytokine-Cytokine Receptor Interaction, TGF-b Path-
AR Regulated Prostate Stromal Cell Gene Expression
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prominent cell signaling pathways were represented in one ranking
or the other.
To better determine whether these gene changes associated with
DHT treatment were specific for the WPMY-AR cells or whether
they might also occur in other human prostate stromal cells with
sufficient AR expression, we transiently transfected PS30 cells with
the AR expression vector or an empty control vector then treated
these cells without or with 10 nM DHT for 72 hrs. RNAs
extracted from these cells were tested by real-time qPCR analysis
Figure 1. Androgen receptor expression and activity in prostate stromal cell lines. (A) AR mRNA levels in PS30, primary prostate stromal
(PrSC), WPMY-1 (W), WPMY-Vec (W-Vec), WPMY-AR (W-AR) or LNCaP cells detected by real-time qPCR of RNAs extracted from the cells. Expression
levels are indexed to the expression of GAPDH in each cell line. (B) AR protein (upper lanes) in PS30, PrSC, W, W-Vec, W-AR or LNCaP cells detected by
Western blot. The blot was re-probed for GAPDH protein (lower lanes) as a control. (C) Luciferase reporter expression in WPMY-1 cells co-transfected
with the ARE-luc reporter vector and a control (empty) vector (Vector) or the pLenti6.2-hAR vector (AR). Luciferase levels are normalized for GFP
fluorescence in the same extract as the transfection control marker. (D) Immunofluorescent staining for AR in W-AR cells grown for 72 hrs in the
absence (left) or presence (right) of 10 nM DHT. Cells were co-stained with DAPI to identify nuclei. (E) Luciferase activity in W-AR cells transfected with
ARE-Luc and GFP in the absence or presence of 10 nM DHT. Luciferase activity was normalized by comparison to GFP levels in the same extract.
(F). Growth of W-Vec or W-AR cells in the absence or presence of 10 nM DHT as measured by the WST-1 assay.
doi:10.1371/journal.pone.0016027.g001
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were selectively analyzed in WPMY-AR cells. The outcomes
showed that AR was expressed 923-fold more in AR-transfected
than in control-transfected PS30 cells. As is shown in Figure 3B,
expression of 6 of the other 10 genes were changed in the same
manner as for the WPMY-AR cells treated with DHT, whereas 4
Figure 2. Gene expression changes associated with expression of AR in the absence or presence of DHT in WPMY-1 prostate
stromal cells. (A) GeneSpring-generated line plot of significant (P,0.05) gene expression differences greater than 1.5-fold in WPMY-Vec cells treated
for 72 hrs with 10 nM DHT. (B) GeneSpring-generated line plot of significant (P,0.05) gene expression differences greater than 1.5-fold in WPMY-AR
cells treated for 72 hrs with 10 nM DHT. (C) GeneSpring-generated line plot of significant (P,0.05) gene expression differences greater than 1.5-fold
between WPMY-Vec and WPMY-AR cells grown without DHT. (D) GeneSpring-generated line plot showing effect of DHT treatment on genes that
were differentially upregulated by 2-fold or greater by AR expression alone (no DHT). (E) GeneSpring generated line plot showing effect of DHT
treatment on genes that were differentially down-regulated by 2-fold or greater by AR expression alone (no DHT) and were subsequently up-
regulated by 2-fold in the presence of DHT. (F) GeneSpring generated line plot showing effect of DHT treatment on genes that were differentially
down-regulated by 2-fold or greater by AR expression alone (no DHT) and were subsequently further down-regulated by 2-fold or greater in the
presence of DHT.
doi:10.1371/journal.pone.0016027.g002
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PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16027Figure 3. Confirmation of microarray-identified androgen-regulated genes (.2-fold changed) by real-time qPCR measurement.
(A). Assessment of individual gene expression changes associated with DHT treatment of WPMY-AR cells by qPCR. Six of the genes in this panel (SFRP-
5, IGF-1, Wnt-16, AQP3, FKBP5 and RERG) were identified as DHT-up-regulated genes in the microarray gene expression analysis and four genes (BMP-
4, FST, IL7R and FGF5) were identified as DHT-down-regulated genes in the microarray gene expression analysis and these changes were confirmed in
the qPCR assay. All changes detected by qPCR were significant changes (P,0.05). (B) Assessment of individual gene expression changes associated
AR Regulated Prostate Stromal Cell Gene Expression
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or DHT-treated cells. Finally, the primary human prostate cell
fibroblasts were also cultured in medium with or without DHT for
72 hrs and RNAs were extracted for real-time qPCR analysis. The
cDNAs from these cells were then assayed for DHT effects on
expression of 5 different genes from our panel. The outcomes
showed that SFRP5 and IGF1 were upregulated by 1.67- to 1.73-
fold by DHT (p,0.05) and FGF5 was downregulated by 1.5-fold
(p,0.05) compared to no-DHT controls whereas expression of
FST and Wnt16 was not significantly changed by DHT treatment
of these cells.
Gene Expression Changes Associated with
Overexpression of AR in WPMY-1 Cells
To determine whether AR expression (in the absence of ligand)
affected gene expression in the WPMY cells, we also compared the
gene expression profiles between WPMY-Vec and WPMY-AR cells
grown without DHT treatment. Remarkably 443 genes were found
to be differentially expressed between these cells at a level of 1.5-fold
or greater (Fig. 2C) and 374 of these genes are differentially
expressed by 2-fold or greater between these cells. In this latter
subset, 55 genes were selectively upregulated and 319 genes were
selectively downregulated in the AR-expressing cells. It was of
further interest to determine how these two categories of genes were
subsequently affected by DHT treatment. First, we selected those
genes(55) that wereupregulated byoverexpressionofAR (at least2-
fold) in the absence of DHT. Sixty percent of these genes (33 genes)
were subsequently downregulated (by 2-fold or greater) again in the
presence of DHT (Fig. 2D) whereas the other 40% were either
unchanged or changed less than 2-fold by DHT and, therefore,
excluded from our analysis. For those 319 genes that were
downregulated by 2-fold or greater by AR overexpression alone,
21 genes (6.58%) were subsequently upregulated by 2-fold or
greater by the addition of DHT (Figure 2E) whereas 21 genes
(6.58%) were further downregulated by 2-fold or greater by the
addition of DHT (Figure 2F). The remaining genes in this category
(277 or 86.8%) were either unchanged by addition of DHT or were
changed less than 2-fold and excluded from our analysis. No genes
were upregulated by AR expression then further upregulated by
DHT even in those that were affected by DHT,2- to 1.5-fold. In
summary, AR overexpression alone in the absence of ligand can
induce but mainly repress expression genes in WPMY-1 cells, but
these effects were sometimes reversed in the presence of ligand.
However, some gene expression changes induced by AR overex-
pression (gene downregulations) were further augmented by the
treatment with the androgen ligand in these cells.
Direct or Indirect Regulation of Genes by DHT
We described here altered patterns of gene expression in prostate
stromal cells induced by AR overexpression, with or without ligand,
that were based upon measurements of mRNA levels. We sought
further to evaluate a small subset of these DHT-regulated genes to
determine whether the effects of DHT required intermediary
protein synthesis. To this end, trypsinized WPMY-AR cells were
allowed to attach overnight and then briefly treated (30 min) with
high dose cycloheximide (40 mgs/ml) to block protein synthesis and
thereafter switched to medium with or without DHT (10 nM)in the
presence of lower dose cycloheximide (10 mgs/ml) for 24 hrs.
Controlcellsweretreatedsimilarlyexceptthatnocyclohexmidewas
included at any time. RNAs extracted from these cells were then
assessed for expression of select DHT-upregulated (RERG, Wnt16
and SFRP5) or DHT-down-regulated (FST, FGF5 and BMP4)
genes. Our results (Figure 4) showed that the DHT effect on
expression changes for four of these genes (RERG, WNT16,
SFRP5, and FST) were not changed by cycloheximide treatment,
whereas the DHT effects on BMP4 and FGF5 expressions were
blocked by cycloheximide.
Effects of DHT-Stimulated WPMY1-AR Conditioned Media
on LNCaP Cell Growth
Finally, we sought to test whether DHT action in the WPMY-
AR model cells might affect the production of secreted factors
Table 1. Hierarchy of KEGG pathway assignments of genes significantly changed by 2-fold or greater in WPMY-AR cells treated
with DHT.
Top KEGG Pathway Ranking Based Upon
the Number of Input Genes in Pathway
# Input Genes
In Pathway
Top KEGG Pathway Ranking Based Upon
the Percent Of Pathway Genes in Input
% Pathway Genes
in Input
Pathways in Cancer 8 TGF-b Pathway 5.747
Cytokine-Cytokine Receptor Interaction 6 Hedgehog Signaling Pathway 3.509
TGF-b Pathway 5 Hematopoietic Pathway 3.448
MAPK Signaling Pathway 5 Cell Adhesion Molecules 2.985
Regulation of Actin Cytoskeleton 4 Wnt Signaling Pathway 2.632
Wnt Signaling Pathway 4 Focal Adhesion 2.463
Neuroactive-Ligand Receptor Pathway 4 Pathways in Cancer 2.424
Hematopoietic Pathway 3 ECM-Receptor Interaction 2.381
Insulin Signaling Pathway 2 Cytokine-Cytokine Receptor Interaction 2.281
Hedgehog Signaling Pathway 2 Type II Diabetes Mellitus 2.222
Genes listed in Table S1 and Table S2 were input into the gene classification alogorithm found at the Pathway Express site (http://vortex.cs.wayne.edu/projects.htm) to
rank the KEGG pathway assignments based upon the numbers of input genes in any given pathway or based upon the percentage of input genes in any given pathway
and the rankings were concordant.
doi:10.1371/journal.pone.0016027.t001
with DHT treatment of PS30 cells transiently transfected with pLenti6.2-hAR by qPCR. Measurement of changes in SRBP5, IGF1, Wnt-16, AQP3, FKBP5,
RERG and FGF5 were significant (P,0.05) whereas changes in BMP-4, FST and IL7R were not significant (P.0.05).
doi:10.1371/journal.pone.0016027.g003
AR Regulated Prostate Stromal Cell Gene Expression
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day conditioned medium from 10 nM DHT-treated WPMY-Vec
or WPMY-AR cells was diluted 1:1 with fresh medium (with
10 nM DHT) and was then added to fresh LNCaP cells
monolayers and the cells were followed for 9 days with medium
replacement every 3 days. Growth over this period was measured
using the WST-1 assay and results are shown in Figure 5.
Treatment with the conditioned medium from the DHT-treated
WPMY-AR cells was found to be significantly more growth-
stimulatory for LNCaP compared to treatment with conditioned
medium from DHT-treated WPMY-Vec cells.
Discussion
Like other tissues, the prostate is made up of an admixture of
disparate cell types that are broadly segregated into an epithelial or
a stromal compartment based upon their localization with regards
to the basement membrane. Prostate cancer cells that are derived
from the prostate epithelium have historically provided the models
to study how androgen action affects prostate cell gene expression.
However, several cell types within the prostate stroma are also
known to express AR in vivo [22–24] and to contribute to the
process(es) through which androgens regulate prostate develop-
ment and disease yet we know very little regarding the effects of
androgen on gene expression in these types of cells. Efforts to this
end are hindered by the lack of suitable cultured stromal cell
models, especially ones that express AR at sufficient levels to allow
the use of contemporary mass gene expression profiling tech-
niques. Here, we attempted to characterize AR expression and
androgen signaling activity in two available immortalized prostate
stromal cell lines, PS30 and WPMY-1, that were previously
reported to express AR [20,25] to assess whether they might
provide models to study androgen regulated gene expression.
These cells are both classified as myofibroblasts based upon their
morphology in culture and their co-expression of vimentin and
smooth muscle actin. We found that both types of cells express
extremely low levels of AR mRNA and protein and neither cell
type responded to DHT treatment after transfection with an
androgen-responsive luciferase reporter vector so neither is likely a
good model for studying androgen regulated gene expression.
However, when the androgen reporter vector was co-transfected
with a wildtype AR expression vector, WPMY-1 cells were then
able to respond to DHT treatment by upregulating androgen-
responsive reporter expression. This result showed that WPMY-1
cells might be made amenable for study of androgen regulated
gene expression when provided with exogenous AR. Transduction
by an antibiotic-selectable AR-expression lentivirus allowed us
then to derive a stable cell line, WPMY-AR, that expressed AR
mRNA and protein at a level comparable to LNCaP cells that are
often used to model a prostate cancer cells’ response to androgens.
The WPMY-AR cells relocated AR protein to the nucleus in the
presence of DHT and appropriately upregulate luciferase
expression from an androgen-regulated reporter vector after
Figure 4. Effects of cycloheximide on gene expression changes in WPMY-AR cells induced by DHT treatment. WPMY-AR cells were pre-
treated then treated with cycloheximide in the absence or presence of 10 nM DHT for 24 hrs. RNAs were analyzed by qPCR for the expression of
RERG, FST or FGF5, as indicated and expression levels were normalized to GAPDH expression levels.
doi:10.1371/journal.pone.0016027.g004
Figure 5. Growth curves of LNCaP cells in the presence of DHT-
treated WPMY-AR conditioned medium (W-AR) or DHT-treated
WPMY-Vec conditioned medium (W-Vec). Relative cell numbers at
different days were estimated by WST-1 assay. Use of conditioned
medium from DHT-treated WPMY-AR cells significantly stimulated
growth (P,0.01, two way ANOVA) of LNCaP cells compared to
conditioned medium from DHT-treated WPMY-Vec cells. Slopes of the
two growth curves were also significantly different (P=0.0181, Linear
Regression Analysis).
doi:10.1371/journal.pone.0016027.g005
AR Regulated Prostate Stromal Cell Gene Expression
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signaling system that is consistent with their use in gene expression
profiling experiments. It was notable that the WPMY-AR cells
were morphologically indistinguishable from parental or control
transduced (WPMY-Vec) cells and that their relative growth rate
(in the presence or absence of androgen) was not significantly
affected by AR overexpression, especially since AR is known to
affect prostate cancer cell growth, either when it is expressed
endogenously or exogenously [26,27].
The WPMY-Vec and WPMY-AR cells were then profiled for
overall gene expression patterns and for changes in these patterns
associated with DHT treatment using a gene Chip microarray
approach. Our preliminary effort involved a more prolonged
treatment with DHT (72 hrs) than is commonly used in studies of
prostate cancer cells, but we hoped that this longer treatment
period would also allow detection of potential secondary gene
expression changes that might be relevant to aspects of cross-talk
between prostate stromal and epithelial cells that affect prostate
development or prostate cancer cell growth. For the WPMY-Vec
control cells, DHT treatment significantly altered the expression of
only 8 genes (out of 28,712 gene probe sets on the Chip) and these
changes were relatively low, ranging from a 1.62- to 1.74-fold
change compared to untreated WPMY-Vec cells. None of these
gene changes were subsequently confirmed using a real-time
qPCR approach. We feel then, that these minor changes in our
control cells (+/2 DHT) detected using the gene Chip microarray
approach represent the ‘‘noise’’ of the system and that this noise is
extremely low and easily filtered using the secondary qPCR
approach. In striking contrast, treatment of WPMY-AR cells with
DHT altered the expression of 141 different genes by 2-fold or
greater. The vast majority of these changes (60.2%) involved gene
expression down-regulations associated with DHT treatment.
Considering that transcriptionally active (liganded) AR is most
often thought of as an inducer of gene expression, this is a
remarkably high number of potentially androgen-repressed genes.
However, AR/androgen repressed genes have been previously
described in prostate cancer cells [8] and one report describing the
effects of androgen on gene expression in LNCaP cells did show
that androgen treatment suppressed almost as many genes as were
induced in these cells [9] so our observation is supported by
observations in other prostate cell systems. It was also interesting
that a comparison of our DHT-changed stromal cell gene lists with
already known androgen-regulated genes assembled at a website
resource (http://argdb.fudan.edu.cn/index_info.php, [28] showed
that approximately 21% of the genes present on our lists (Tables
S1 and S2) were previously described to be ‘‘androgen regulated’’
based on surveyed literature sources mainly involving studies of
prostate cancer cells. The presence of this significant percentage of
previously described ‘‘androgen regulated’’ genes on our lists
supports the idea that we are identifying many genes that may be
commonly regulated by liganded AR in many types of prostate
cells as well as genes that may be selectively affected by AR/
androgens in prostate stromal cells.
With regards to the nature of these DHT-regulated stromal cell
genes, there were few, if any genes that are functionally classified
as regulators of cell proliferative processes or apoptosis and this is
consistent with our observations that androgen treatment did not
significantly affect WPMY-AR growth. The assessment of gene
function for the up-regulated/down-regulated genes on our lists
based upon KEGG pathway designation was remarkable since it
identified a predominance of genes that are involved in generic
‘‘cancer pathways’’ that might be relevant to our findings that
conditioned medium from DHT-stimulated WPMY-AR cells
affected LNCaP cell growth. Likewise, the presence of multiple
genes on our list classified as effectors of the cytokine-cytokine
receptor signaling, TGF-b, WNT, Hedgehog or MAP Kinase
signaling pathways would support previous published studies
suggesting that these particular signaling pathways are involved in
the cross-talk that occurs between prostate stromal and prostate
epithelial/cancer cells in development or disease [29–31].
Categorization of genes on the list based upon Gene Ontology
(GO) assignments were also done using the DAVID program and
the outcome showed similar categories to those assigned under the
KEGG Pathway (not shown). Finally, our limited survey for an
effect of cycloheximide on DHT-induced gene changes does
support the idea that many of the gene changes we observed are
primarily associated with AR functional activity. Yet our ability to
identify some DHT-affected genes in WPMY-AR cells that were
not changed when cycloheximide was included with DHT
treatment also shows that there are genes on our lists that are
secondarily regulated by some other protein affected by DHT as
we suspected. Use of WPMY-AR cells with a shorter period of
DHT treatment may help us sort out the primary affected vs the
secondary affected genes and we will attempt this in the future.
For validation purposes, we had selected a panel of 10 genes from
our lists of DHT-changed genes and all 10 of them were confirmed to
be appropriately changed by DHT using an alternate assay (real-time
qPCR). We believe that this limited effort helps validate the outcome of
the overall gene expression profiling for androgen regulated prostate
stromal cell genes, especially when we focus on those genes that were
changed by 2-fold or greater. Moreover, 7 of these 10 select genes were
similarly changed by DHT when we assessed a different prostate
stromal cell line, PS30, that was only transiently transfected with the
AR expression vector. Considering that the WPMY-AR cells were
more enriched for AR expressing cells by stable antibiotic selection, it is
possible thatall 10genes inthis panel would besimilarlyregulatedif we
had also selected the AR-expressing PS30 population with antibiotic.
However, this outcome still indicates that there is effective similarity in
gene changes induced by liganded AR in WPMY-1 cells as in the PS30
cells. Finally, 4 of 7 genes from this panel were also shown to be
regulated by DHT in a similar manner in cultured primary prostate
stromal cells that were not manipulated to overexpress AR. Although
these primary prostate fibroblasts express AR mRNA in a similar
range to the PS30 and WPMY-1 cells, we were, at least, able to show
that these cells had increased nuclear AR immunostaining (Figure S1)
when they were cultured in DHT so this supports the idea that
endogenous AR in primary prostate stromal cells operates in a similar
fashion to exogenous AR in the WPMY-AR cells.
Finally, our results were noteworthy in that they showed a
significanteffectofARexpression alone(intheabsenceofligand)on
the gene expression patterns of WPMY-1 cells. In fact, there were
more gene changes between control (WPMY-Vec) cells and
WPMY-AR cells than were found after DHT treatment of
WPMY-AR cells. The gene changes associated with AR overex-
pression alone were even more highly repressive than after DHT
treatment in that 85% of genes changed by AR overexpression
alone involved gene down-regulation. This raises some concern
since our immunostaining work showed that most of the AR
expressed in WPMY-AR was cytoplasmically localized in the
absence of DHT. It may be that the unliganded AR has an effect on
gene expression in WPMY-AR cells through a non-genomic
pathway similar to that described in some types of prostate cancer
cells where the receptor interacts with cell membrane complex to
effect gene changes [32]. However, since there was, at least,
minimal nuclear AR immunostaining in non-treated WPMY-AR
cells that was not observed in cells similarly stained with IgG non-
immune antibody, it is more likely that some exogenous AR
expressed in WPMY-AR was afforded accessto the nucleus where it
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were significantly more repressive of gene expression in the absence
of ligand. Genomic action of unliganded AR in our model is also
supported by the fact that addition of DHT reversed or amplified
(by at least 2-fold) the expression of 23.5% of the genes that were
changed by AR expression alone.
Finally, we attempted to test whether DHT treatment affects the
WPMY-AR cells by altering their output of soluble factors that
influence prostate cancer cell growth. We chose LNCaP as the cancer
test cell model despite the complication introduced by its own
endogenous androgen sensitivity because it best represents the
phenotype of the prostate cancer cell found in the natural situation.
To address the complication of LNCaP’s endogenous androgen
sensitivity, our approach involved the use of conditioned medium
from WPMY-AR or WPMY-Vec cells, both treated with DHT, that
was then supplemented into fresh medium that also contained DHT.
Here, the WPMY-AR conditioned medium significantly increased
the growth of the LNCaP cells over 9 days, compared to the WPMY-
Vec conditioned medium. Consistent with this result, we found that
LNCaP cells grown for 7 days in WPMY-AR conditioned medium
expressed 2.7-fold less p21 mRNA than cells grown in WPMY-Vec
conditioned medium. The outcome of this experiment implies either
that androgen action selectively increased the production and release
of some factor from WPMY-AR cells that increased LNCaP growth
or that it reduced the production of some inhibitory factor (made
more abundantly by WPMY-Vec cells) that suppresses LNCaP
growth. Regardless of the mechanism, this experimental outcome
further supports the idea that androgen action in AR-positive
fibroblasts has consequences for prostate cancer growth.
In summary, we believe that our efforts represent a step towards
identifying the role of AR/androgens in prostate stromal cell gene
expression and prostate biology. We have created a cell model to
study androgen action on prostate stromal cell genes and we have
shown thatthismodelcell respondstoandrogen stimulationinsome
ways that are sometimes similar to prostate cancer cells but mostly
differssignificantlyfromprostate cancercellsthatareusuallyusedto
model androgen effects on prostate cell gene expression. In our
stromal cell model, AR alone is remarkably suppressive of gene
expression, yet this effect does not alter their superficial cell
morphology nor growth behavior. We believe this effect involves
interaction of AR with the prostate stromal cell genome since it can
often be reversed or augmented when ligand is provided. Through
the use of gene profiling technology, we have provided a
preliminary list of genes that are affected by liganded AR function
and several of these same genes are also affected by DHT treatment
of other types of prostate stromal cells that overexpress exogenous
AR or primary prostate stromal cells that simply express low levels
of endogenous AR. Many of the androgen affected genes are
associated withsignalingpathwaysinvolvedinstromal-epithelialcell
cross-talk in the prostate or with cancer pathways. This latter
category of genes affected by androgens was consistent with our
findings that conditioned medium from androgen-stimulated
WPMY-AR cells more support prostate cancer cell growth than
from androgen-stimulated control cells that lack AR. Collectively,
the work represents a preliminary characterization that can be
extended in the future to significantly enhance our understanding of
androgen function in human prostate stromal cells.
Materials and Methods
Cells and Reagents
Benign immortalized human prostate stromal cells, WPMY-1
[20] were obtained from ATCC (Manassas, VA); PS30 cells [25]
were kindly provided by Debra Schwinn (Duke University, NC);
and primary human prostate stromal fibroblasts were grown from
a non-cancerous region of a human prostate [33] as previously
described. Human prostate cancer, LNCaP cells, were purchased
from ATCC. PS30 and LNCaP cells were cultured in RPMI-1640
(Hyclone, Waltham, MA) supplemented with 10% heat-inactivat-
ed fetal bovine serum (FBS) (Hyclone), 1% penicillin/streptomy-
cin, 1% glutamine and 1% sodium pyruvate (Invitrogen, Inc.,
Carlsbad, NC). WPMY cells were cultured in Dulbecco’s Modified
Eagle’s Medium (Hyclone) supplemented 10% FBS, 1% penicil-
lin/streptomycin, 1% glutamine and 1% sodium pyruvate.
Charcoal/dextran-Stripped FBS (CS-FBS) was obtained from
Hyclone. Dihydrotestosterone (DHT) was obtained from Sigma-
Aldrich Chemical Co. (St. Louis, MO). Mouse monoclonal anti-
human AR antibody (clone 441) and mouse monoclonal anti-
human GAPDH (clone 6C5) was purchased from Santa Cruz
Biosciences (Santa Cruz, CA). Secondary sheep anti-mouse HRP
was purchased from GE Healthcare (Pittsburgh, PA). Blastocidin S
HCl was purchased from Invitrogen (Carlsbad, CA).
DNA Vectors and Cell Manipulation Procedures
An androgen reporter vector with a synthetic androgen-
responsive promoter (ARE-Luc, Panomics, Inc., Fremont, CA)
and pEGFP (Clontech, Mountain View, CA) were transfected into
cells using Lipofectamine 2000 (Invitrogen). Replication-deficient
lentivirus pLenti6-hAR was derived from inserting the human AR
full length wildtype cDNA into the pLenti6.2 plasmid (Invitrogen).
Conditioned medium containing infectious virus was obtained by
transfection of 293FT HEK cells with pLenti6-hAR or pLenti6.2
(empty vector control) along with accessory lentiviral packaging
plasmids VSV-G and delta 8.91. Medium from these transfected
cells was collected 48 hrs after transfection and was filtered. Stable
cells were derived after incubation with viral conditioned medium
for 48 hrs followed by selection in fresh medium containing in
Blasticidin S (1 mg/ml, Invitrogen) and were pooled and
designated WPMY-Vec (pLenti6.2 empty vector) or WPMY-AR
(pLenti6-hAR).
Gene Expression Profiling Using Gene Chip Microarrays
WPMY-Vec or WPMY-AR cells were trypsinized then plated at
1610
6 cells per 60 mm dish in DMEM with 10% FBS. After
overnight attachment, medium was removed, plates were rinsed
with PBS and fresh medium with 10% CS-FBS, with or without
10 nM DHT was added and cells were maintained for 72 hrs.
Cells were washed with PBS then lysed and RNA was purified
with the RNEasy Plus micro kit (Qiagen Inc., Valencia, CA) as
directed by the manufacturer. Individual RNAs were analyzed for
RNA quality by Bioanalyzer Chips (Agilent Technologies, Santa
Clara, CA) and only RNAs with a RIN of 9.0 or higher we used
for subsequent gene expression profiling. RNA labeling and
hybridization were performed by the Ordway Research Institute
microarray core facility according to the Affymetrix microarray
analysis protocols. Briefly, single-standed cDNA was generated
from amplified cRNA with the WT cDNA Synthesis Kit
(Affymetrix, Santa Clara, CA) and then fragmented a labeled
with the WT Terminal Labeling Kit (Affymetrix) s. Samples were
hybridized with Affymetrix Human ST 1.0 Gene Chips (Affyme-
trix) and scanned on the Affymetrix Gene Chip Scanner 3000 in
the core facility and were collected into CEL files for further
analysis. Resulting signal analysis was performed with GeneSpring
GX 11.0.2 (Agilent Technologies) software. Expressions of genes
under different conditions was filtered by statistical significance
(students T-test, p.0.05) by GeneSpring program and compar-
isons between treatment groups fold induction cut-offs of 1.5 or 2.0
fold or higher between sample groups.
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Cells (biological duplicate specimens) were lysed and total RNAs
were extracted using the RNeasy mini-kit (Qiagen, Inc.). RNA
concentrations were estimated by absorbance at 260 nm. First
strand cDNA synthesis was performed using the SuperScript
TM III
First-Strand Synthesis System for qRT-PCR (Invitrogen). Gene-
specific primer sets used for real-time analysis are described in
Table S1. Primer sets (0.5 mM) were mixed with cDNA template
and RT
2 SYBR Green Master Mix (SABiosciences, Inc.,
Frederick, MD), and qRT-PCR was performed using an ABI
Prism 7900 HT sequence detector as previously described [34].
Relative mRNA expression levels were determined by comparison
to the GAPDH internal control and plotted as ratio to GAPDH
expression values.
Luciferase Assay
Cells were seeded into 6 well plates at 2610
5 cells per well. After
overnight attachment, cells were transfected with 2 mg pLenti6.2
or pLenti6-hAR with 1.5 mg ARE-Luc reporter vector and 0.5 mg
pEGFP. Medium was changed after 4 hrs to DMEM with 10%
CS-FBS with or without DHT as indicated. After 72 hrs, medium
was removed, cells were lysed in 1% Triton X-100 buffer, and the
lysates analyzed by on a Fluostar Optima fluorometer (for GFP
fluorescence) (BMG Labtechnologies, Durham, NC) and on a 20/
20n Luminometer (Turner Biosystems, Sunnyvale, CA) after
incubation with firefly luciferase reagent (Promega, Inc., Madison,
WI). GFP values were used to normalize luciferase values and data
is presented as a ratio of luciferase to GFP levels.
Western Blot Analysis
Sub-confluent monolayers of cells were lysed and their protein
contents measured as was previously described [35]. SDS-PAGE
loading dye was added to aliquots containing equal protein
amounts from each cell line, boiled, and loaded onto an SDS-
PAGE gel for electrophoresis. The gel was electro-transferred to a
nitrocellulose membrane, blocked in 5% milk, and probed with
anti-AR or anti-GAPDH antibodies overnight. The membrane
was then washed, and probed with sheep anti-mouse conjugated
HRP (GE Healthcare, UK). After incubation, the membrane was
washed, treated with ECL reagent (SuperSignal West Pico
Chemiluminescent Substrate, Thermo Scientific, Rockford, IL)
and exposed to x-ray film.
Conditioned Medium Preparation and LNCaP
Proliferation Assay
WPMY1-Vector or WPMY1-AR cells were plated at 3610
6
cells in a 100 mm culture dish in RPMI with 10% CS-FBS
supplemented with 10 nM DHT and grown for 72 hrs. Medium
was then filtered through a 0.22 mm filter and used immediately or
frozen. LNCaP cells were plated in 96 well plates (5000 cells/well)
in replicates of 6 wells per assay condition or incubation day. After
attachment, medium was removed and wells were treated with a
1:1 mixture of RPMI, 10% CS-FBS, 10 nM DHT with 72 hr
conditioned medium from WPMY1-Vector or WPMY1-AR cells.
Medium was changed every three days. WST-1 reagent (Dojindo
Laboratories, Kamimashiki, Japan) was added to individual wells
at 3-day intervals for 9 days and the plate was then read after
90 min at 450 nm (SpectraMax M2 plate reader, Molecular
Diagnostics, Sunnyvale, CA). Values for six samples at each point
were averaged and data was graphed as absorbance vs time.
Statistical Analysis
Comparative quantitative RT-PCR outcomes from DHT-
untreated/-treated cells were based on 2 measurements each from
2 biological replicate samples and they were statistically analyzed
using a two-tailed students T test. Differences in the growth curves
of LNCaP cells grown with different conditioned stromal cell
medium were analyzed by two-way Anova and curve slopes were
compared using multiple linear regression analysis. P Values of
#0.05 were considered significant.
Supporting Information
Table S1. Primers used in qPCR reactions.
(DOC)
Table S2. Genes up-regulated by 2-fold or greater in
WPMY-AR cells by DHT. * Indicates genes that were
previously described to be androgen regulated.
(DOC)
Table S3. Genes down-regulated by 2-fold or greater in
WPMY-AR cells by DHT. * Indicates genes that were
previously described to be androgen regulated.
(DOC)
Figure S1. AR expression in primary human prostate
stromal cells (PrSC). Primary cell cultures were incubated for
24 h with vehicle (ethanol, a) or 10 nM DHT (b) before
immunostaining. Cells were fixed in 4% p-formaldehyde and
stained with a polyclonal antibody against AR (Santa Cruz
Biotechnology). Immunoreaction was visualized using a secondary
antibody HRP-conjugated. AR nuclear translocation was evident
in presence of DHT (b-c, high magnification picture). Images a
and b: x300. Image c: x600.
(TIF)
Author Contributions
Conceived and designed the experiments: RB MJT MC AG. Performed
the experiments: MJT RCW MC MS AG. Analyzed the data: MC MJT
MS RB. Contributed reagents/materials/analysis tools: MS AG GS BM.
Wrote the paper: RB MJT MC AG GS. Obtained permission for use of
cell line: RB AG.
References
1. Imperato-McGinley J, Zhu YS (2002) Androgens and male physiology the
syndrome of 5alpha reductase-2 deficiency. Mol Cell Endocrinol 198: 51–59.
2. Sultan C, Lumbroso S, Poujol N, Belon C, Boudon C, et al. (1993) Mutations of
androgen receptor gene in androgen insensitivity syndromes. J Steroid Biochem
Mol Biol 46: 519–530.
3. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA (2009)
Chemoprevention of prostate cancer. J Urol 182: 499–507.
4. Miyamoto H, Messing EM, Chang C (2004) Androgen deprivation therapy for
prostate cancer: current status and future prospects. Prostate 61: 332–353.
5. Dehm SM, Tindall DJ (2006) Molecular regulation of androgen action in
prostate cancer. J Cell Biochem 99: 333–344.
6. Xu LL, Su YP, Labiche R, Segawa T, Shanmugam N, et al. (2001) Quantitative
expression profile of androgen-regulated genes in prostate cancer cells and
identification of prostate-specific genes. Int J Cancer 92: 322–328.
7. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, et al. (2004) Identification
and validation of novel androgen-regulated genes in prostate cancer. Endocrinol
145: 3913–3924.
8. Jariwala U, Prescott J, Jia L, Barski A, Pregizer S, et al. (2007) Identification of
novel androgen receptor target genes in prostate cancer. Mol Cancer 6: 39.
9. Ngan S, Stronach EA, Photiou A, Waxman J, Ali S, et al. (2009) Microarray
coupled to quantitative RT-PCR analysis of androgen-regulated genes in human
LNCaP prostate cancer cells. Oncogene 28: 2051–2063.
AR Regulated Prostate Stromal Cell Gene Expression
PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e1602710. Liu AY, Corey E, Vessella RL, Lange PH, True LD, et al. (1997) Identification
of differentially expressed prostate genes: increased expression of transcription
factor ETS-2 in prostate cancer. Prostate 30: 145–153.
11. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, et al. (2005) Frequent
overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.
Oncogene 24: 3847–3852.
12. Rostad K, Mannelqvist M, Halvorsen OJ, Oyan AM, Bo TH, et al. (2007) ERG
upregulation and related ETS transcription factors in prostate cancer. Int J Oncol
30: 19–32.
13. Hu P, Greenwood CM, Beyene J (2007) Integrative analysis of gene expression
data including an assessment of pathway enrichment for predicting prostate
cancer. Cancer Inform 2: 289–300.
14. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, et al. (2009)
Candidate pathways and genes for prostate cancer: a meta-analysis of gene
expression data. BMC Med Genomics 2: 48.
15. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW (1991)
Acceleration of human prostate cancer growth in vivo by factors produced by
prostate and bone fibroblasts. Cancer Res 51: 3753–3761.
16. Cunha GR, Hayward SW, Wang YZ (2002) Role of stroma in carcinogenesis of
the prostate. Differentiation 70: 473–485.
17. Cunha GR, Hayward SW, Wang YZ, Ricke WA (2003) Role of the stromal
microenvironment in carcinogenesis of the prostate. Int J Cancer 107: 1–10.
18. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, et al. (2004)
Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic
development. J Steroid Biochem Mol Biol 92: 221–236.
19. Chung LW, Baseman A, Assikis V, Zhau HE (2005) Molecular insights into
prostate cancer progression: the missing link of tumor microenvironment. J Urol
173: 10–20.
20. Webber MM, Trakul N, Thraves PS, Bello-DeOcampo D, Chu WW, et al.
(1999) A human prostatic stromal myofibroblast cell line WPMY-1: a model for
stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis 20:
1185–1192.
21. Draghici S, Khatri P, Tarca AL, Amin K, Done A, et al. (2007) A systems
biology approach for pathway level analysis. Genome Res 17: 1537–1545.
22. Sar M, Lubahn DB, French FS, Wilson EM (1990) Immunohistochemical
localization of the androgen receptor in rat and human tissues. Endocrinol 127:
3180–3186.
23. Iwamura M, Abrahamsson PA, Benning CM, Cockett AT, di Sant’Agnese PA
(1994) Androgen receptor immunostaining and its tissue distribution in formalin-
fixed, paraffin-embedded sections after microwave treatment. J Histochem
Cytochem 42: 783–788.
24. Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, et al. (1996) Androgen
and glucocorticoid receptors in the stroma and epithelium of prostatic
hyperplasia and carcinoma. Clin Cancer Res 2: 889–895.
25. Price DT, Rudner X, Michelotti GA, Schwinn DA (2000) Immortalization of a
human prostate stromal cell line using a recombinant retroviral approach. J Urol
164: 2145–2150.
26. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, et al. (2009) In vivo
knockdown of the androgen receptor results in growth inhibition and regression
of well-established, castration-resistant prostate tumors. Clin Cancer Res 15:
39–47.
27. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, et al. (1997)
Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell
cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol
126: 59–73.
28. Jiang M, Ma Y, Chen C, Fu X, Yang S, et al. (2009) Androgen-responsive gene
database: integrated knowledge on androgen-responsive genes. Mol Endocrinol
23: 1927–1933.
29. Shigemura K, Isotani S, Wang R, Fujisawa M, Gotoh A, et al. (2009) Soluble
factors derived from stroma activated androgen receptor phosphorylation in
human prostate LNCaP cells: roles of ERK/MAP kinase. Prostate 69: 949–955.
30. Basanta D, Strand DW, Lukner RB, Franco OE, Cliffel DE, et al. (2009) The
role of transforming growth factor-beta-mediated tumor-stroma interactions in
prostate cancer progression: an integrative approach. Cancer Res 69:
7111–7120.
31. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, et al. (2008)
Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a
signaling axis. Oncogene 27: 7118–7130.
32. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, et al. (2004) Changes in
androgen receptor nongenotropic signaling correlate with transition of LNCaP
cells to androgen independence. Cancer Res 64: 7156–7168.
33. Cano P, Godoy A, Escamilla R, Dhir R, Onate SA (2007) Stromal-epithelial cell
interactions and androgen receptor-coregulator recruitment is altered in the
tissue microenvironment of prostate cancer. Cancer Res 67: 511–519.
34. Mechlin CW, Tanner MJ, Chen M, Buttyan R, Levin RM, et al. (2010) Gli2
expression and human bladder transitional carcinoma cell invasiveness. J Urol
184: 344–351.
35. Chen M, Tanner M, Levine AC, Levina E, Ohouo P, et al. (2009) Androgenic
regulation of hedgehog signaling pathway components in prostate cancer cells.
Cell Cycle 8: 149–157.
AR Regulated Prostate Stromal Cell Gene Expression
PLoS ONE | www.plosone.org 11 January 2011 | Volume 6 | Issue 1 | e16027